TGW 101
Alternative Names: TGW-101Latest Information Update: 03 Jul 2025
At a glance
- Originator Tagworks Pharmaceuticals
- Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunoglobulin Fv fragments; Immunotoxins; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 25 Apr 2025 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 22 Apr 2025 Phase-I clinical trials in Solid tumours (Late-stage disease) in USA (Parenteral) (NCT06959706)
- 22 Apr 2025 US FDA approves IND application for TGW 101 in Solid tumours